Polyclonal Antibody to Low Density Lipoprotein Receptor Adaptor Protein 1 (LDLRAP1)
Code | Size | Price |
---|
PAD104Mu01-20ul | 20ul | £88.00 |
Quantity:
PAD104Mu01-100ul | 100ul | £165.00 |
Quantity:
PAD104Mu01-200ul | 200ul | £223.00 |
Quantity:
PAD104Mu01-1ml | 1ml | £512.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Host Type: Rabbit
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Mouse
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ARH1; ARH; ARH2; FHCB1; FHCB2; Autosomal recessive hypercholesterolemia protein
Buffer Formulation:
0.01M PBS, pH7.4, containing 0.01% Proclin-300, 50% glycerol.
Item Name:
Low Density Lipoprotein Receptor Adaptor Protein 1
Reactivity:
Hu;Ra;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.5-2ug/mL;1:350-1400
Immunohistochemistry: 5-20ug/mL;1:35-140
Immunocytochemistry: 5-20ug/mL;1:35-140
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:35-140
Immunocytochemistry: 5-20ug/mL;1:35-140
Optimal working dilutions must be determined by end user.
Related Products
Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Recombinant Low Density LiPoprotein Receptor Adaptor Protein 1 (LDLRAP1) | RPD104Mu01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||